ALXN has 1 bil in sales with a 20 bil MC right this minute.
I think ALXN gets their high market cap due to their focus on rare orphan-type diseases (don't think CML is apples-to-apples to the diseases ALXN focuses on) that lends to them essentially having markets to themself with high margins. Besides, who is to say that ALXN isn't overvalued? ; )
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.